BVT Aktienanleihe SNW 31.12.2024/ DE000VM58T58 /
2024-05-13 8:03:26 PM | Chg.+0.370 | Bid9:37:45 PM | Ask9:37:45 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
100.580EUR | +0.37% | 100.610 Bid Size: 50,000 |
101.150 Ask Size: 50,000 |
SANOFI SA INHABER ... | 88.61 EUR | 2024-12-31 | Call |
GlobeNewswire
1:00 PM
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 20...
GlobeNewswire
12:00 PM
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...
GlobeNewswire
7:00 AM
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...
GlobeNewswire
05-10
Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVI...
GlobeNewswire
05-08
IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
05-07
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
GlobeNewswire
05-02
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant R...
GlobeNewswire
04-25
Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance
GlobeNewswire
04-23
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
GlobeNewswire
04-17
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in ...